Maximilian is a Research Officer within LSE Health and CPEC and a part-time PhD student in the Department of Health Policy at LSE. He holds an MSc in Health Policy, Planning and Financing from LSE and the London School of Hygiene and Tropical Medicine and a BSc in Business, Economics and Social Sciences from the Vienna University of Economics and Business (WU).
Maximilian’s research interests include pharmaceutical regulation and policy, evidence synthesis, comparative effectiveness research, decision-making at the patient and population levels, and economic evaluation.
He currently works on the Horizon 2020-funded IMPACT-HTA project, investigating discrepancies in treatment effects between randomised and non-randomised studies and assessing the performance of novel methods for analysing and adjusting observational data.
He has previously worked on the IMI2-funded “Big Data for Better Outcomes” initiative, investigating methodological challenges arising from increased availability of data and their use for health care decision-making. He has also collaborated with cardiologists across Europe on the FP7-funded CARDIOPROOF project to review and summarise the evidence base for interventions in congenital heart disease, evaluated the potential for cost savings in this disease area, and assessed the potential of novel image-based simulation modelling tools to impact on clinical decision-making.
Maximilian’s PhD research focuses on evidence requirements for drug marketing authorisation. His empirical work includes an evaluation of evidence standards in expedited approval pathways, focusing on uncertainty and the role of non-randomised studies for regulatory decision-making.